PD06-1: Darolutamide in combination with androgen-deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer by disease volume and risk in the phase 3 ARASENS trial

PD06-2: Real-world Study on Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients Using a Urology Network in the United States (DEAR Study)

PD06-3: Inhibition of LGALS1 Enhances ENZ Sensitivity in AR-Expressing Prostate Cancer Cells by Suppressing Energy Metabolism

PD06-4: Prostate Health Index (PHI) Aids Prostate Cancer Detection in the Grey Zone of MRI- (PI-RADS 3) Lesions

PD06-5: Anastomotic urinary leakage after Retzius-sparing robot-assisted radical prostatectomy.

PD06-6: The association between sarcopenia and postoperative outcomes after robotic assisted radical prostatectomy